EA201791421A1 - Антитела против csf1r для лечения pvns - Google Patents
Антитела против csf1r для лечения pvnsInfo
- Publication number
- EA201791421A1 EA201791421A1 EA201791421A EA201791421A EA201791421A1 EA 201791421 A1 EA201791421 A1 EA 201791421A1 EA 201791421 A EA201791421 A EA 201791421A EA 201791421 A EA201791421 A EA 201791421A EA 201791421 A1 EA201791421 A1 EA 201791421A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pvns
- treatment
- antibodies against
- csf1r
- against csf1r
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Раскрыты способы лечения пигментного виллезонодулярного синовита (PVNS) антителами, которые связывают рецептор колониестимулирующего фактора 1 (CSF1R).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462095297P | 2014-12-22 | 2014-12-22 | |
US201562163251P | 2015-05-18 | 2015-05-18 | |
PCT/US2015/067012 WO2016106180A1 (en) | 2014-12-22 | 2015-12-21 | Anti-csf1r antibodies for treating pvns |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201791421A1 true EA201791421A1 (ru) | 2017-10-31 |
Family
ID=55135539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791421A EA201791421A1 (ru) | 2014-12-22 | 2015-12-21 | Антитела против csf1r для лечения pvns |
Country Status (16)
Country | Link |
---|---|
US (3) | US10040858B2 (ru) |
EP (1) | EP3237447B1 (ru) |
JP (1) | JP6797801B2 (ru) |
KR (1) | KR20170096187A (ru) |
CN (1) | CN107257806B (ru) |
AU (1) | AU2015369854B2 (ru) |
BR (1) | BR112017013111A2 (ru) |
CA (1) | CA2969341C (ru) |
EA (1) | EA201791421A1 (ru) |
ES (1) | ES2843586T3 (ru) |
HK (1) | HK1245804A1 (ru) |
IL (1) | IL252716A0 (ru) |
MX (1) | MX2017008218A (ru) |
SG (1) | SG11201704792UA (ru) |
TW (1) | TW201630937A (ru) |
WO (1) | WO2016106180A1 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Antibodies against PD-L1 |
AU2018256406A1 (en) | 2017-04-19 | 2019-10-17 | Marengo Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2019173361A2 (en) | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
CN108948199B (zh) * | 2018-07-18 | 2019-06-21 | 博奥信生物技术(南京)有限公司 | 抗人csf-1r单克隆抗体及其用途 |
CN109053887B (zh) * | 2018-07-18 | 2019-07-23 | 博奥信生物技术(南京)有限公司 | 一种抗人csf-1r单克隆抗体及用途 |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
MX2021002935A (es) * | 2018-09-13 | 2021-06-15 | Hoffmann La Roche | Formulacion de anticuerpos contra csf-1r. |
CN113164777A (zh) | 2018-09-27 | 2021-07-23 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
TW202112812A (zh) | 2019-05-24 | 2021-04-01 | 香港商安立璽榮生醫(香港)有限公司 | Csf1r抗體、il10融合蛋白及其用途 |
WO2024059508A2 (en) * | 2022-09-12 | 2024-03-21 | AmMax Bio, Inc. | Treatment of tenosynovial giant cell tumor |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1989003687A1 (en) | 1987-10-23 | 1989-05-05 | Genetics Institute, Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0955365A3 (en) | 1992-06-09 | 2000-12-20 | Chiron Corporation | Crystallization of M-CSF |
US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
WO2000025803A1 (fr) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Preparations contenant une proteine betacelluline |
WO2001030381A2 (de) | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
WO2002102972A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
AU2003291002A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
ES2630224T3 (es) | 2003-10-22 | 2017-08-18 | Keck Graduate Institute | Métodos para sintetizar polipéptidos heteromultiméricos en levadura con el uso de una estrategia de apareamiento haploide |
GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
EP1706137A2 (en) | 2004-01-21 | 2006-10-04 | Chiron Corporation | M-csf muteins and uses thereof |
CA2565974A1 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
JP5435865B2 (ja) | 2004-07-22 | 2014-03-05 | ファイブ プライム セラピューティクス, インコーポレイテッド | 疾患処置におけるmgd−csfのための組成物およびその使用方法 |
WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
CN101384621A (zh) | 2005-11-10 | 2009-03-11 | 受体生物公司 | 产生受体和配体同种型的方法 |
WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
US20100099123A1 (en) | 2005-12-22 | 2010-04-22 | Novartis Ag | Soluble Human M-CSF Receptor and Uses Thereof |
WO2007081879A2 (en) | 2006-01-05 | 2007-07-19 | Novartis Ag | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
EA018917B1 (ru) | 2006-04-19 | 2013-11-29 | Новартис Аг | 6-о-замещенные бензоксазолы и бензотиазолы и способы подавления передачи сигналов от csf-1r |
EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
CA2669599A1 (en) | 2006-11-17 | 2008-05-22 | Biogen Idec Ma Inc. | Systemic administration of colony stimulating factors to treat amyloid associated disorders |
DE602008004296D1 (de) | 2007-02-14 | 2011-02-17 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
BRPI0812159A2 (pt) | 2007-05-21 | 2017-05-02 | Novartis Ag | inibidores de csf-1r, composições e métodos de uso |
US20100298217A1 (en) | 2007-05-30 | 2010-11-25 | Evan Richard Stanley | Csf-1r mutants |
RS56743B1 (sr) | 2007-08-21 | 2018-03-30 | Amgen Inc | Humani c-fms antigen vezujući proteini |
US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
WO2009050228A2 (en) | 2007-10-18 | 2009-04-23 | Novartis Ag | Csf-1r inhibitors for treatment of cancer and bone diseases |
EP2215482A2 (en) | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
US20110262425A1 (en) | 2007-12-12 | 2011-10-27 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
KR101633520B1 (ko) | 2008-03-14 | 2016-06-24 | 트랜스진 에스.에이. | Csf-1r에 대한 항체 |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2780692C (en) | 2009-12-10 | 2018-09-11 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
SG181861A1 (en) | 2009-12-21 | 2012-07-30 | Array Biopharma Inc | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
PL2566517T3 (pl) | 2010-05-04 | 2019-04-30 | Five Prime Therapeutics Inc | Przeciwciała wiążące csf1r |
TW201307845A (zh) | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用il-17拮抗劑治療關節炎的方法 |
WO2013057290A1 (en) | 2011-10-21 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
CA2851771C (en) | 2011-10-21 | 2018-09-11 | Transgene Sa | Modulation of macrophage activation |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
KR102199273B1 (ko) * | 2012-03-26 | 2021-01-06 | 닛뽕 케미파 가부시키가이샤 | 뼈 및 연부에 발생하는 거대 세포성 종양 또는 연골 육종의 예방 및 치료제 |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
BR112014028013A2 (pt) | 2012-05-11 | 2018-02-27 | Five Prime Therapeutics Inc | métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea |
EP3679949A1 (en) | 2012-08-31 | 2020-07-15 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
-
2015
- 2015-12-21 SG SG11201704792UA patent/SG11201704792UA/en unknown
- 2015-12-21 TW TW104143045A patent/TW201630937A/zh unknown
- 2015-12-21 KR KR1020177020158A patent/KR20170096187A/ko unknown
- 2015-12-21 JP JP2017533421A patent/JP6797801B2/ja active Active
- 2015-12-21 US US14/976,346 patent/US10040858B2/en active Active
- 2015-12-21 EA EA201791421A patent/EA201791421A1/ru unknown
- 2015-12-21 MX MX2017008218A patent/MX2017008218A/es unknown
- 2015-12-21 ES ES15823889T patent/ES2843586T3/es active Active
- 2015-12-21 CN CN201580076553.8A patent/CN107257806B/zh active Active
- 2015-12-21 AU AU2015369854A patent/AU2015369854B2/en active Active
- 2015-12-21 BR BR112017013111A patent/BR112017013111A2/pt not_active Application Discontinuation
- 2015-12-21 WO PCT/US2015/067012 patent/WO2016106180A1/en active Application Filing
- 2015-12-21 CA CA2969341A patent/CA2969341C/en active Active
- 2015-12-21 EP EP15823889.9A patent/EP3237447B1/en active Active
-
2017
- 2017-06-06 IL IL252716A patent/IL252716A0/en unknown
-
2018
- 2018-04-18 HK HK18105046.3A patent/HK1245804A1/zh unknown
- 2018-06-22 US US16/015,371 patent/US10730949B2/en active Active
-
2020
- 2020-06-25 US US16/911,806 patent/US20210009700A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016106180A1 (en) | 2016-06-30 |
EP3237447B1 (en) | 2020-12-02 |
IL252716A0 (en) | 2017-08-31 |
AU2015369854B2 (en) | 2021-07-01 |
US10730949B2 (en) | 2020-08-04 |
EP3237447A1 (en) | 2017-11-01 |
HK1245804A1 (zh) | 2018-08-31 |
JP6797801B2 (ja) | 2020-12-09 |
TW201630937A (zh) | 2016-09-01 |
US20190119390A1 (en) | 2019-04-25 |
CN107257806A (zh) | 2017-10-17 |
KR20170096187A (ko) | 2017-08-23 |
CA2969341C (en) | 2023-07-04 |
BR112017013111A2 (pt) | 2018-05-15 |
ES2843586T3 (es) | 2021-07-19 |
MX2017008218A (es) | 2017-10-18 |
US10040858B2 (en) | 2018-08-07 |
CA2969341A1 (en) | 2016-06-30 |
CN107257806B (zh) | 2021-08-10 |
JP2018501254A (ja) | 2018-01-18 |
AU2015369854A1 (en) | 2017-06-15 |
US20210009700A1 (en) | 2021-01-14 |
US20160185869A1 (en) | 2016-06-30 |
SG11201704792UA (en) | 2017-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791421A1 (ru) | Антитела против csf1r для лечения pvns | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
PH12016501763A1 (en) | Multispecific antibodies | |
CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
EA201790173A1 (ru) | Антитела, связывающие axl | |
MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
EA201790967A1 (ru) | Химерные антигенные рецепторы против cldn и способы их применения | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
IL249393B (en) | Methods for treating conditions with antibodies that bind colony-stimulating factor receptor 1 (csf1r) | |
EA201700060A1 (ru) | Терапевтическое средство для кератоконъюнктивальных расстройств | |
AR103227A1 (es) | Anticuerpos anti-csf1r para el tratamiento de svp | |
EA201792249A1 (ru) | Комбинированная терапия злокачественной опухоли | |
UA114708U (uk) | Тяговий привід електробуса | |
TN2014000522A1 (fr) | لوح مدرسي بوجهين | |
TN2014000384A1 (fr) | نظام صوتي ذكي وآمن | |
NZ744340A (en) | Anti-jagged1 antibodies and methods of use | |
TH1501004525A (th) | ตัวควบคุมเอนไซม์ที่ดัดแปรเมธิล, องค์ประกอบ และการใช้สารเหล่านั้น |